Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Incidence of second cancers after allogeneic hematopoietic stem cell transplantation using reduced-dose radiation.

Hsieh MM, Fitzhugh CD, Tisdale JF.

Blood. 2009 Jul 2;114(1):225; author reply 225-6. doi: 10.1182/blood-2009-03-209015. No abstract available.

2.

Myelodysplastic syndromes complicating hematopoietic stem cell transplantation.

Fassas AB, Tricot G.

Cancer Treat Res. 2001;108:169-84. Review. No abstract available.

PMID:
11702599
3.

Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation.

Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ.

Biol Blood Marrow Transplant. 2001;7(4):223-9. Review.

PMID:
11349809
4.

Malignancies after hematopoietic stem cell transplantation: many questions, some answers.

Deeg HJ, Socie G.

Blood. 1998 Mar 15;91(6):1833-44. Review. No abstract available.

5.

Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems.

Adès L, Guardiola P, Sociè G.

Blood Rev. 2002 Jun;16(2):135-46. Review.

PMID:
12127957
7.

[Ten years of changes in conditioning regimen for allogenic hematopoietic stem cell transplantation in adults].

Peffault de Latour R, Cabrespine-Faugeras A, Bay JO.

Bull Cancer. 2008 Jan;95(1):87-97. doi: 10.1684/bdc.2008.0555. Review. French.

8.

Stem cell transplantation in Hodgkin lymphoma.

Murphy F, Sirohi B, Cunningham D.

Expert Rev Anticancer Ther. 2007 Mar;7(3):297-306. Review.

PMID:
17338650
9.

Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?

Adkins DR, DiPersio JF.

Curr Opin Hematol. 2008 Nov;15(6):555-60. doi: 10.1097/MOH.0b013e32831188f5. Review.

PMID:
18832925
10.

Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies.

Adhikari J, Sharma P, Bhatt VR.

Future Oncol. 2015;11(23):3175-85. doi: 10.2217/fon.15.252. Epub 2015 Nov 9. Review.

PMID:
26551415
11.

Secondary cancers following allogeneic haematopoietic cell transplantation in adults.

Majhail NS.

Br J Haematol. 2011 Aug;154(3):301-10. doi: 10.1111/j.1365-2141.2011.08756.x. Epub 2011 May 26. Review.

PMID:
21615719
12.
13.

Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation.

Socié G, Rizzo JD.

Semin Hematol. 2012 Jan;49(1):4-9. doi: 10.1053/j.seminhematol.2011.10.013. Review.

PMID:
22221779
14.

[Role of cardiac bio-markers in monitoring of cardiotoxicity after hematopoietic stem cell transplantation].

Roziaková L, Mladosievičová B.

Vnitr Lek. 2013 Nov;59(11):996-1002. Review. Czech.

PMID:
24279444
15.

Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK.

Nat Rev Clin Oncol. 2013 May;10(5):289-301. doi: 10.1038/nrclinonc.2013.41. Epub 2013 Mar 26. Review.

PMID:
23529000
16.

Second malignant neoplasms following hematopoietic stem cell transplantation.

Friedman DL, Leisenring W, Schwartz JL, Deeg HJ.

Int J Hematol. 2004 Apr;79(3):229-34. Review.

PMID:
15168589
17.

[Virus infection after allogeneic hematopoietic stem cell transplantation].

Takenaka K.

Rinsho Ketsueki. 2013 Oct;54(10):1940-50. Review. Japanese. No abstract available.

PMID:
24064847
18.

Long-term care after stem-cell transplantation.

Socié G, Tichelli A.

Hematol J. 2004;5 Suppl 3:S39-43. Review. No abstract available.

PMID:
15190276
19.

Late effects of hematopoietic stem cell transplantation.

Kansu E.

Hematology. 2005;10 Suppl 1:238-44. Review. No abstract available.

PMID:
16188682
20.

Chronic kidney disease after hematopoietic stem cell transplantation.

Cohen EP, Pais P, Moulder JE.

Semin Nephrol. 2010 Nov;30(6):627-34. doi: 10.1016/j.semnephrol.2010.09.010. Review.

Supplemental Content

Support Center